02 March 2022: Clinical Research
Retrospective Study of the Association Between Platelet-to-Lymphocyte Ratio in Patients with Acute Coronary Syndrome on Admission to a Rural Referral Center in East Java, Indonesia, and the Incidence of New Symptomatic Heart Failure at 6 Months
Ryan Enast Intan 1ACEF* , Firas Farisi Alkaff 23CEF* , Yudi Her Oktaviono 1D , Ricardo Adrian Nugraha 1ACD , Tan Nicko Octora 4B , Michael Jonatan 1AF , Dimas Rio Balti 5ABEF , Fani Suslina Hasibuan 6B , Basuni Radi 78D , Anwar Santoso 78ADDOI: 10.12659/MSM.935002
Med Sci Monit 2022; 28:e935002
Table 2 In-hospital and long-term outcomes of patients with acute coronary syndrome.
| Variables | TotalN=92 | PLR median group | OR (95% CI) | p-value | |
|---|---|---|---|---|---|
| High (≥108)n=46 | Low (<108)n=46 | ||||
| Acute lung oedema, n (%) | 37 (40.2) | 23 (50.0) | 14 (30.4) | 1.39 (0.98–1.96) | 0.058 |
| Cardiogenic Shock, n (%) | 12 (13.04) | 6 (13.0) | 6 (13.0) | 1.00 (0.85–1.17) | 1.000 |
| Life threatening arrhythmia, n (%) | 14 (15.38) | 9 (19.6) | 5 (10.9) | 1.11 (0.93–1.32) | 0.384 |
| Length of stay, median [IQR] | 4 [–]4 | 4 [–]4 | 4 [–]4 | 1.00 (0.99–1.04) | 0.893 |
| First HF symptom during 6-month follow up (NYHA class II–IV) (%) | 65 (70.65) | 41 (89.13) | 24 (52.17) | 1.70 (1.33–2.18) | |
| MACE during 6-month follow up | 10 (10.86) | 4 (8.69) | 6 (13.04) | 0.67 (0.24–1.41) | 0.738 |
| HF – heart failure; IQR – interquartile range; PLR – platelet-to-lymphocyte ratio; MACE – major adverse cardiac events; OR – odds ratio; PLR – platelet-to-lymphocyte ratio; NYHA – New York Heart Association. value | |||||